ClinicalTrials.gg
CompletedNCT00124449Updated Apr 7, 2015Results posted

Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients

A Phase 2 interventional study of Abatacept and placebo in Arthritis, Rheumatoid, sponsored by Bristol-Myers Squibb. Completed at 48 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-04-07.

Sponsored by Bristol-Myers Squibb · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
41st of 63
56 · median 119
Started
2005
with 3 others
Phase 2
9 of 63
1 open now
Registered
5th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 41st largest by enrollment, is one of 4 that started in 2005, is one of 9 in phase 2, and was the 5th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to assess if Abatacept given for six months will prevent rheumatoid arthritis (RA) in patients who are at risk for the development of RA in comparison to placebo. High risk patients are defined as those having a positive laboratory test for anti-cyclic citrullinated peptide (anti-CCP2).

03

Conditions studied

  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of undifferentiated arthritis
  • Clinical synovitis of two or more joints
  • At least one but not more than three of the criteria for diagnosis of RA (1987).
  • No prior disease modifying anti-rheumatic drugs (DMARDs)/biologics.
  • Duration of disease must be 18 months or less.
  • Positive for antibodies against cyclic citrullinated peptides.

Exclusion criteria

Exclusion Criteria:

  • Women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy.
  • Active vasculitis of a major organ system.
  • Severe or recurrent bacterial infection.
  • History of cancer in the last five years except certain skin cancers.
  • Herpes zoster that resolved less than 2 months prior to enrollment
05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Active comparator
    1

    Drug: Abatacept

  • Placebo comparator
    2

    Drug: placebo

Interventions

  • solution, intravenous injection, monthly, 169 days weight based: \<60 kg = 500 mg 60 to 100 kg = 750 mg \>100 kg = 1 g

    Also known as: Orencia

  • Drugplacebo

    solution, intravenous injection, 0 mg, monthly, 169 days

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) by American Rheumatism Association (ARA) Criteria and/or Discontinued Due to Lack of Efficacy

    ARA criteria is a 7-item tool for RA classification purposes; a patient is said to have RA (meeting endpoint) if he or she has satisfied at least 4 of the 7 criteria. If a participant discontinued due to lack of efficacy, he/she was regarded as meeting primary endpoint also.

    Time frame: 12 months

Secondary outcomes

  1. Number of Participants With a Diagnosis of RA by 1987 ARA Criteria and/or Discontinued Due to Lack of Efficacy

    ARA criteria is a 7-item tool for classification purposes; a patient is said to have RA (meeting endpoint) if he or she has satisfied at least 4 of the 7 criteria. If a participant discontinued due to lack of efficacy, he/she was regarded as meeting endpoint also.

    Time frame: 24 months

  2. Number of Participants With Undifferentiated Inflammatory Arthritis (UA) Who Develop Another Rheumatic Disease

    Clinical diagnosis of other rheumatic diseases at 12 and 24 months. If a participant discontinued due to lack of efficacy, he/she was regarded as meeting endpoint also.

    Time frame: 12 months, 24 months

  3. Change From Baseline in Radiographic Erosion and Joint Space Narrowing Score at 6 Months, 12 Months, and 24 Months

    Mean change from baseline using the Genant-Modified Sharp Score. Erosion score=assessment of 14 sites in each hand and wrist + 6 joints in each foot, using an 8-point scale from 0 (no erosions) to 3.5 (erosions of 100% or articular surfaces). Joint score= assessment of 13 sites in each wrist and hand + 6 sites in each foot using a 9-point scale from 0 (normal) to 4.0 (definite ankylosis). As-observed data. Change from Baseline=postbaseline score at timepoint (6 or 12 or 24 months) minus baseline score; a lower value signifies improvement.

    Time frame: Baseline, 6 months, 12 months, 24 months

  4. Change From Baseline in Total Erosion, Edema, Synovitis Scores at 6 Months, 12 Months, and 24 Months

    Mean change from baseline. Degree of synovitis and structural joint damage (erosion, edema) of the carpal and metacarpophalangeal joints, as measured by magnetic resonance imaging (MRI) scores using the European League Against Rheumatism (EULAR)-Outcome Measures in Rheumatology Clinical Trials (OMERACT) assessment. Edema scale=0 (no bone involved) to 3 (67% to 100% of bone involved). Synovitis scale=0 (normal) and 1-3 (mild, moderate, severe. Bone erosion scale=0 (0% of bone involved) to 10 (91% to 100% of bone involved). Change from baseline=postbaseline score at timepoint - baseline score.

    Time frame: Baseline, 6 months, 12 months, 24 months

  5. Number of Participants With Persistent Symptomatic Clinical Synovitis

    Synovitis, assessed by clinical signs and symptoms

    Time frame: 6, 12, and 24 months

  6. Short Form-36 (SF-36) Physical and Mental Component Summary (PCS and MCS) Scores - Mean Change From Baseline

    SF-36, a 36-item instrument that covers 8 quality of life domains, which were used to derive the physical and mental component summary scores, which ranged from 0 to 100, with higher scores indicating a better quality of life. Change from baseline=postbaseline - baseline value; a higher value signifies improvement.

    Time frame: 6 months, 12 months, 24 months

  7. Change From Baseline in Cytokine Levels and Second Generation Anti-cyclic Citrullinated Peptide (Anti-CCP2) Antibodies at 6 Months, 12 Months, and 24 Months

    To assess pharmacodynamic effect of abatacept on serum levels of autoantibodies, mean change from baseline in cytokines (interleukin-6 \[IL-6\], interleukin-1B \[IL-1B\], tumor necrosis factor Alpha \[TNF-Alpha\], Matrix Metalloproteinase 3T \[MMP3T\], and anti-CCP2), as measured by standard laboratory investigations, were assessed. Change from baseline=postbaseline value at timepoint (6 or 12 or 24 months) minus baseline value; a lower value signifies improvement.

    Time frame: Baseline, 6 Months, 12 months, 24 months

  8. Number of Participants With Anti-CCP2 Positive and/or Rheumatoid Factor (RF) Positive Over Time

    To assess the pharmacodynamic effect of abatacept on serum levels of autoantibodies, number of participants with Anti-CCP2 Positive of Rheumatoid Factor (RF) positive

    Time frame: Day 1, 6 months, 12 months, 24 months

  9. Frequency of Human Leukocyte Antigen (HLA) Typing

    To assess the pharmacodynamic effect of abatacept on serum levels of autoantibodies, a blood sample was obtained for HLA typing to determine the presence or absence of alleles associated with RA susceptibility and severity (shared epitope alleles HLA-DRB10401 and HLA-DRB10404).

    Time frame: Day 1

  10. DAS 28 C Reactive Protein (CRP) Score - Mean Change From Baseline

    The DAS 28 (CRP) is a composite of 4 variables: 28 tender joint count, 28 swollen joint count, CRP, and subject assessment of disease activity measure on a VAS of 100 mm. Change from Baseline=postbaseline score-baseline score; a lower value signifies improvement.

    Time frame: 6 months, 12 months, 24 months

  11. Number of Participants With a DAS 28 (CRP) Score of ≤3.2 (Low Disease Activity) or <2.6 (in Remission)

    The DAS 28 (CRP) is a composite of 4 variables: tender joint count, swollen joint count, CRP, and subject assessment of disease activity measure on a VAS of 100 mm. Scores for disease activity are defined as low (≤ 3.2) and in remission (\< 2.6).

    Time frame: 6 months, 12 months, 24 months

  12. Number of Subjects With Health Assessment Questionnaire (HAQ) Disability Index Response

    This questionnaire includes 20 questions assessing physical function in 8 domains. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do. Higher scores indicate greater dysfunction. HAQ response =improvement of at least 0.3 units from baseline.

    Time frame: 6 months, 12 months, 24 months

  13. Overall Safety - Adverse Events (AEs), Serious AEs, and Deaths

    AEs were monitored at all scheduled visits of the study drug treatment and observation periods and at the follow-up visits performed 28, 56, and 85 days after the last infusion of study medication for participants who were withdrawn prematurely

    Time frame: Throughout the treatment period (6 months)

  14. Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies

    Immunogenicity, as measured by the number of positive repsonses for serum levels of abatacept-specific antibodies measured by enzyme-linked immunosorbent assays (ELISA). Postive response for whole molecule assessment was a value of \> 400 and for tip assessment was ≥25.

    Time frame: Up to 12 months

07

Results

Posted Nov 19, 2009

Participant flow

6-month Double-Blind Treatment Period
Participant flow — 6-month Double-Blind Treatment Period
MilestoneAbataceptPlacebo
Started2828
Completed2217
Not completed611
Withdrew: Adverse event10
Withdrew: Lack of efficacy38
Withdrew: Withdrawal by subject11
Withdrew: Poor/noncompliance10
Withdrew: Sponsor request01
Withdrew: Exposure to mycobacterium tuberculosis01
18-Month Untreated Observation Period
Participant flow — 18-Month Untreated Observation Period
MilestoneAbataceptPlacebo
Started2217
Completed year 1 of study149
Completed74
Not completed1513
Withdrew: Adverse event01
Withdrew: Lack of efficacy1112
Withdrew: Lost to follow-up10
Withdrew: Pregnancy10
Withdrew: Poor/noncompliance10
Withdrew: Relocated10

Outcome measures

PrimaryNumber of Participants With a Diagnosis of Rheumatoid Arthritis (RA) by American Rheumatism Association (ARA) Criteria and/or Discontinued Due to Lack of Efficacy

ARA criteria is a 7-item tool for RA classification purposes; a patient is said to have RA (meeting endpoint) if he or she has satisfied at least 4 of the 7 criteria. If a participant discontinued due to lack of efficacy, he/she was regarded as meeting primary endpoint also.

Time frame:
12 months
Reported as:
Number · Participants
Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) by American Rheumatism Association (ARA) Criteria and/or Discontinued Due to Lack of Efficacy
ParticipantsAbataceptPlacebo
Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) by American Rheumatism Association (ARA) Criteria and/or Discontinued Due to Lack of Efficacy1216
SecondaryNumber of Participants With a Diagnosis of RA by 1987 ARA Criteria and/or Discontinued Due to Lack of Efficacy

ARA criteria is a 7-item tool for classification purposes; a patient is said to have RA (meeting endpoint) if he or she has satisfied at least 4 of the 7 criteria. If a participant discontinued due to lack of efficacy, he/she was regarded as meeting endpoint also.

Time frame:
24 months
Reported as:
Number · Participants
Number of Participants With a Diagnosis of RA by 1987 ARA Criteria and/or Discontinued Due to Lack of Efficacy
ParticipantsAbataceptPlacebo
Number of Participants With a Diagnosis of RA by 1987 ARA Criteria and/or Discontinued Due to Lack of Efficacy1721
SecondaryNumber of Participants With Undifferentiated Inflammatory Arthritis (UA) Who Develop Another Rheumatic Disease

Clinical diagnosis of other rheumatic diseases at 12 and 24 months. If a participant discontinued due to lack of efficacy, he/she was regarded as meeting endpoint also.

Time frame:
12 months, 24 months
Reported as:
Number · Participants
Number of Participants With Undifferentiated Inflammatory Arthritis (UA) Who Develop Another Rheumatic Disease
ParticipantsAbataceptPlacebo
12 months (n=26; n=24)00
24 months (n=23; n=24)00
SecondaryChange From Baseline in Radiographic Erosion and Joint Space Narrowing Score at 6 Months, 12 Months, and 24 Months

Mean change from baseline using the Genant-Modified Sharp Score. Erosion score=assessment of 14 sites in each hand and wrist + 6 joints in each foot, using an 8-point scale from 0 (no erosions) to 3.5 (erosions of 100% or articular surfaces). Joint score= assessment of 13 sites in each wrist and hand + 6 sites in each foot using a 9-point scale from 0 (normal) to 4.0 (definite ankylosis). As-observed data. Change from Baseline=postbaseline score at timepoint (6 or 12 or 24 months) minus baseline score; a lower value signifies improvement.

Time frame:
Baseline, 6 months, 12 months, 24 months
Reported as:
Mean · units on a scale
Change From Baseline in Radiographic Erosion and Joint Space Narrowing Score at 6 Months, 12 Months, and 24 Months
units on a scaleAbataceptPlacebo
Erosion Score 6 months (n=22; n=21)0.13 ± 0.090.46 ± 0.24
Joint Space Narrowing 6 months (n=22; n=21)0.00 ± 0.000.01 ± 0.01
Total Score 6 months (n=22; n=21)0.13 ± 0.090.47 ± 0.24
Erosion Score 12 months (n=17; n=11)0.02 ± 0.040.85 ± 0.39
Joint Space Narrowing 12 months (n=17; n=11)0.00 ± 0.000.26 ± 0.22
Total Score 12 months (n=17; n=11)0.02 ± 0.041.11 ± 0.56
Erosion Score 24 months (n=7; n=3)0.04 ± 0.04-0.17 ± 0.17
Joint Space Narrowing 24 months (n=7; n=3)0.00 ± 0.000.00 ± 0.00
Total Score 24 months (n=7; n=3)0.04 ± 0.04-0.17 ± 0.17
SecondaryChange From Baseline in Total Erosion, Edema, Synovitis Scores at 6 Months, 12 Months, and 24 Months

Mean change from baseline. Degree of synovitis and structural joint damage (erosion, edema) of the carpal and metacarpophalangeal joints, as measured by magnetic resonance imaging (MRI) scores using the European League Against Rheumatism (EULAR)-Outcome Measures in Rheumatology Clinical Trials (OMERACT) assessment. Edema scale=0 (no bone involved) to 3 (67% to 100% of bone involved). Synovitis scale=0 (normal) and 1-3 (mild, moderate, severe. Bone erosion scale=0 (0% of bone involved) to 10 (91% to 100% of bone involved). Change from baseline=postbaseline score at timepoint - baseline score.

Time frame:
Baseline, 6 months, 12 months, 24 months
Reported as:
Mean · units on a scale
Change From Baseline in Total Erosion, Edema, Synovitis Scores at 6 Months, 12 Months, and 24 Months
units on a scaleAbataceptPlacebo
Erosion Score at 6 months (n=11; n=10)0.45 ± 0.371.20 ± 1.09
Edema Score at 6 months (n=11; n=10)-1.64 ± 1.481.40 ± 1.59
Synovitis Score at 6 months (n=11; n=10)0.27 ± 0.561.60 ± 1.23
Erosion Score at 12 months (n=9; n=6)0.00 ± 0.175.00 ± 3.20
Edema Score at 12 months (n=9; n=6)0.22 ± 0.496.67 ± 4.22
Synovitis Score at 12 months (n=9; n=6)0.22 ± 0.222.33 ± 1.61
Erosion Score at 24 months (n=5; n=2)0.80 ± 0.490.00 ± 0.00
Edema Score at 24 months (n=5; n=2)0.20 ± 0.200.50 ± 0.50
Synovitis Score at 24 months (n=5; n=2)0.60 ± 0.601.50 ± 2.50
SecondaryNumber of Participants With Persistent Symptomatic Clinical Synovitis

Synovitis, assessed by clinical signs and symptoms

Time frame:
6, 12, and 24 months
Reported as:
Number · Participants
Number of Participants With Persistent Symptomatic Clinical Synovitis
ParticipantsAbataceptPlacebo
6 months (n=5; n=12)412
12 months (n=11; n=7)107
24 months (n=3; n=2)32
SecondaryShort Form-36 (SF-36) Physical and Mental Component Summary (PCS and MCS) Scores - Mean Change From Baseline

SF-36, a 36-item instrument that covers 8 quality of life domains, which were used to derive the physical and mental component summary scores, which ranged from 0 to 100, with higher scores indicating a better quality of life. Change from baseline=postbaseline - baseline value; a higher value signifies improvement.

Time frame:
6 months, 12 months, 24 months
Reported as:
Mean · units on a scale
Short Form-36 (SF-36) Physical and Mental Component Summary (PCS and MCS) Scores - Mean Change From Baseline
units on a scaleAbataceptPlacebo
PCS, 6 months (n=26; n=20)10.23 ± 1.681.95 ± 1.52
MCS, 6 months (n=26; n=20)2.54 ± 1.33-0.30 ± 1.29
PCS, 12 months (n=20; n=14)3.83 ± 2.38-0.81 ± 2.26
MCS, 12 months (n=20; n=14)2.50 ± 1.75-2.89 ± 2.85
PCS, 24 months (n=7; n=5)2.46 ± 3.15-2.17 ± 6.44
MCS, 24 months (n=7; n=5)3.75 ± 1.99-3.30 ± 7.58
SecondaryChange From Baseline in Cytokine Levels and Second Generation Anti-cyclic Citrullinated Peptide (Anti-CCP2) Antibodies at 6 Months, 12 Months, and 24 Months

To assess pharmacodynamic effect of abatacept on serum levels of autoantibodies, mean change from baseline in cytokines (interleukin-6 \[IL-6\], interleukin-1B \[IL-1B\], tumor necrosis factor Alpha \[TNF-Alpha\], Matrix Metalloproteinase 3T \[MMP3T\], and anti-CCP2), as measured by standard laboratory investigations, were assessed. Change from baseline=postbaseline value at timepoint (6 or 12 or 24 months) minus baseline value; a lower value signifies improvement.

Time frame:
Baseline, 6 Months, 12 months, 24 months
Reported as:
Mean · laboratory values
Change From Baseline in Cytokine Levels and Second Generation Anti-cyclic Citrullinated Peptide (Anti-CCP2) Antibodies at 6 Months, 12 Months, and 24 Months
laboratory valuesAbataceptPlacebo
IL6 at 6 months (n=19, n=18)-4.49 ± 1.781.08 ± 0.72
IL6 at 12 months (n=13, n=7)-0.14 ± 1.616.37 ± 3.81
IL6 at 24 months (n=5, n=3)-3.44 ± 3.540.90 ± 1.51
IL1B at 6 months (n=18, n=18)-0.12 ± 0.07-0.09 ± 0.08
IL1B at 12 months (n=13, n=7)-0.09 ± 0.07-0.24 ± 0.21
IL1B at 24 months (n=5, n=1)0.20 ± 0.200.00 ± 0.00
TNF-Alpha at 6 months (n=18, n=18)-1.70 ± 1.290.07 ± 0.28
TNF-Alpha at 12 months (n=13, n=7)-0.50 ± 0.25-0.10 ± 0.33
TNF-Alpha at 24 months (n=13, n=7)-0.82 ± 0.47-0.03 ± 0.03
MMP3T at 6 months (n=20, n=19)-2.29 ± 4.8614.34 ± 9.85
MMP3T at 12 months (n=15, n=9)-2.55 ± 3.0825.34 ± 14.59
MMP3T at 24 months (n=6, n=3)6.73 ± 6.933.10 ± 3.45
Anti-CCP2 antibodies at 6 months (n=21, n=19)-94.5 ± 29.4916.32 ± 21.49
Anti-CCP2 antibodies at 12 months (n=14, n=10)-6.46 ± 48.09149.5 ± 64.38
Anti-CCP2 antibodies at 24 months (n=6, n=3)3.43 ± 53.85-35.1 ± 55.65
SecondaryNumber of Participants With Anti-CCP2 Positive and/or Rheumatoid Factor (RF) Positive Over Time

To assess the pharmacodynamic effect of abatacept on serum levels of autoantibodies, number of participants with Anti-CCP2 Positive of Rheumatoid Factor (RF) positive

Time frame:
Day 1, 6 months, 12 months, 24 months
Reported as:
Number · Participants
Number of Participants With Anti-CCP2 Positive and/or Rheumatoid Factor (RF) Positive Over Time
ParticipantsAbataceptPlacebo
Anti-CCP2 Positive on Day 1 (n=28, n=28)2828
Anti-CCP2 Positive at 6 months (n=22, n=19)2019
Anti-CCP2 Positive at 12 months (n=15, n=10)1310
Anti-CCP2 Positive at 24 months (n=6, n=3)53
RF on Day 1 (n=28, n=28)2420
RF at 6 months (n=22, n=20)1314
RF at 12 months (n=15, n=10)118
RF at 24 months (n=6, n=3)33
SecondaryFrequency of Human Leukocyte Antigen (HLA) Typing

To assess the pharmacodynamic effect of abatacept on serum levels of autoantibodies, a blood sample was obtained for HLA typing to determine the presence or absence of alleles associated with RA susceptibility and severity (shared epitope alleles HLA-DRB10401 and HLA-DRB10404).

Time frame:
Day 1
Reported as:
Number · participants
Frequency of Human Leukocyte Antigen (HLA) Typing
participantsAbataceptPlacebo
Missing47
Undetected1110
Detected1311
SecondaryDAS 28 C Reactive Protein (CRP) Score - Mean Change From Baseline

The DAS 28 (CRP) is a composite of 4 variables: 28 tender joint count, 28 swollen joint count, CRP, and subject assessment of disease activity measure on a VAS of 100 mm. Change from Baseline=postbaseline score-baseline score; a lower value signifies improvement.

Time frame:
6 months, 12 months, 24 months
Reported as:
Mean · units on a scale
DAS 28 C Reactive Protein (CRP) Score - Mean Change From Baseline
units on a scaleAbataceptPlacebo
6 Months (n=20; n=20)-1.13 ± 0.200.01 ± 0.26
12 Months (n=18; n=13)-0.50 ± 0.22-0.05 ± 0.42
24 Months (n=6; n=4)-0.33 ± 0.330.69 ± 1.16
SecondaryNumber of Participants With a DAS 28 (CRP) Score of ≤3.2 (Low Disease Activity) or <2.6 (in Remission)

The DAS 28 (CRP) is a composite of 4 variables: tender joint count, swollen joint count, CRP, and subject assessment of disease activity measure on a VAS of 100 mm. Scores for disease activity are defined as low (≤ 3.2) and in remission (\< 2.6).

Time frame:
6 months, 12 months, 24 months
Reported as:
Number · Participants
Number of Participants With a DAS 28 (CRP) Score of ≤3.2 (Low Disease Activity) or <2.6 (in Remission)
ParticipantsAbataceptPlacebo
≤3.2 at 6 months (n=21; n=20)179
<2.6 at 6 months (n=21; n=20)157
≤3.2 at 12 months (n=19; n=13)137
<2.6 at 12 months (n=19; n=13)95
≤3.2 at 24 months (n=7; n=4)52
<2.6 at 24 months (n=7; n=4)42
SecondaryNumber of Subjects With Health Assessment Questionnaire (HAQ) Disability Index Response

This questionnaire includes 20 questions assessing physical function in 8 domains. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do. Higher scores indicate greater dysfunction. HAQ response =improvement of at least 0.3 units from baseline.

Time frame:
6 months, 12 months, 24 months
Reported as:
Number · Participants
Number of Subjects With Health Assessment Questionnaire (HAQ) Disability Index Response
ParticipantsAbataceptPlacebo
6 Months (n=26; n=25)166
12 months (n=25; n=25)93
24 months (n=21; n=24)31
SecondaryOverall Safety - Adverse Events (AEs), Serious AEs, and Deaths

AEs were monitored at all scheduled visits of the study drug treatment and observation periods and at the follow-up visits performed 28, 56, and 85 days after the last infusion of study medication for participants who were withdrawn prematurely

Time frame:
Throughout the treatment period (6 months)
Reported as:
Number · Participants
Overall Safety - Adverse Events (AEs), Serious AEs, and Deaths
ParticipantsAbataceptPlacebo
Deaths00
SAEs11
AEs1820
Related AEs1410
Discontinued due to AEs11
SecondaryNumber of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies

Immunogenicity, as measured by the number of positive repsonses for serum levels of abatacept-specific antibodies measured by enzyme-linked immunosorbent assays (ELISA). Postive response for whole molecule assessment was a value of \> 400 and for tip assessment was ≥25.

Time frame:
Up to 12 months
Reported as:
Number · participants
Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies
participantsAbatacept
Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies4

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMS-188667—1/28 (3.6%)16/28 (57.1%)
Placebo—1/28 (3.6%)13/28 (46.4%)
Most frequent serious events
Most frequent serious events
EventBMS-188667Placebo
SCIATICANervous system disorders0/281/28
BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/280/28
Most frequent other events
Showing 10 of 18
Most frequent other events
EventBMS-188667Placebo
DIARRHOEAGastrointestinal disorders4/283/28
PHARYNGOLARYNGEAL PAINRespiratory, thoracic and mediastinal disorders1/284/28
HEADACHENervous system disorders3/282/28
GASTROENTERITISInfections and infestations0/283/28
NASOPHARYNGITISInfections and infestations3/282/28
URINARY TRACT INFECTIONInfections and infestations2/283/28
NAUSEAGastrointestinal disorders0/282/28
VOMITINGGastrointestinal disorders2/280/28
CONSTIPATIONGastrointestinal disorders0/282/28
RHINITISInfections and infestations0/282/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)AbataceptPlaceboTotal
Mean44.8 ± 10.944.7 ± 12.144.8 ± 11.4
Age, Continuous
Age, Continuous(years)AbataceptPlaceboTotal
Median43.5 (23.0 to 74.0)44.0 (26.0 to 71.0)44.0 (23.0 to 74.0)
Sex: Female, Male
Sex: Female, Male(Participants)AbataceptPlaceboTotal
Female202040
Male8816
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AbataceptPlaceboTotal
White252348
Black134
Asian112
Other112
Region of Enrollment
Region of Enrollment(participants)AbataceptPlaceboTotal
North America6511
South America527
Europe172138
Months of Undifferentiated Inflammatory Arthritis (UA)
Months of Undifferentiated Inflammatory Arthritis (UA)(Months)AbataceptPlaceboTotal
Mean8.8 ± 4.27.1 ± 4.47.9 ± 4.3
Weight
Weight(Kilograms)AbataceptPlaceboTotal
Mean75.9 ± 22.570.9 ± 13.973.4 ± 18.7
08

Study locations

48 sites
  • Local Institution
    Huntsville, Alabama, United States
  • Local Institution
    Mobile, Alabama, United States
  • Local Institution
    Huntington Beach, California, United States
  • Local Institution
    Los Angeles, California, United States
  • Local Institution
    Boulder, Colorado, United States
  • Local Institution
    Colorado Springs, Colorado, United States
  • Local Institution
    Ft. Lauderdale, Florida, United States
  • Local Institution
    Chicago, Illinois, United States
  • Local Institution
    Evansville, Indiana, United States
  • Local Institution
    New Orleans, Louisiana, United States
  • Local Institution
    Cumberland, Maryland, United States
  • Local Institution
    Hagerstown, Maryland, United States
  • Local Institution
    Duluth, Minnesota, United States
  • Local Institution
    Durham, North Carolina, United States
  • Local Institution
    Wilmington, North Carolina, United States
  • Local Institution
    Oklahoma City, Oklahoma, United States
  • Local Institution
    Willow Grove, Pennsylvania, United States
  • Local Institution
    Charleston, South Carolina, United States
  • Local Institution
    Austin, Texas, United States
  • Local Institution
    Arlington, Virginia, United States
  • Local Institution
    Cairns, Queensland, Australia
  • Local Institution
    Clayton, Victoria, Australia
  • Local Institution
    Malvern, Victoria, Australia
  • Local Institution
    Shenton Park, Western Australia, Australia
  • Local Institution
    Bruxelles, Belgium
  • Local Institution
    Leuven, Belgium
  • Local Institution
    Paris, France
  • Local Institution
    Strasbourg Cedex, France
  • Local Institution
    Berlin, Germany
  • Local Institution
    Dresden, Germany
  • Local Institution
    Hamburg, Germany
  • Local Institution
    Hannover, Germany
  • Local Institution
    Heidelberg, Germany
  • Local Institution
    Bari, Italy
  • Local Institution
    Ferrara, Italy
  • Local Institution
    Milano, Italy
  • Local Institution
    Guadalajara, Distrito Federal, Mexico
  • Local Institution
    Leon, Guanajuato, Mexico
  • Local Institution
    Guadalajara, Jalisco, Mexico
  • Local Institution
    Morelia, Michioacan, Mexico
  • Local Institution
    Ponce, Puerto Rico
  • Local Institution
    A Coruna, Spain
  • Local Institution
    Barcelona, Spain
  • Local Institution
    Madrid, Spain
  • Local Institution
    Oviedo, Spain
  • Local Institution
    Sevilla, Spain
  • Local Institution
    Liverpool, Merseyside, United Kingdom
  • Local Institution
    Leeds, North Yorkshire, United Kingdom
09

References and documents

Publications

  • Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, Genant HK, Peterfy C, Mitra P, Overfield S, Qi K, Westhovens R. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010 Mar;69(3):510-6. doi: 10.1136/ard.2009.119016. Epub 2009 Nov 23. Erratum In: Ann Rheum Dis. 2011 Aug;70(8):1519. PubMed 19933744 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of May 2007 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2005
First posted
Jul 28, 2005
Start
Feb 2005
Primary completionActual
May 2007
CompletionActual
Apr 2008
Results first posted
Nov 19, 2009
Last update
Apr 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00124449
First posted
Jul 28, 2005
Start date
Feb 2005
Primary completion
May 2007
Completion
Apr 2008
Results posted
Nov 19, 2009
Last update
Apr 7, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion